小肠腺癌发病机制研究进展

doi:10.12092/j.issn.1009-2501.2018.02.018

中国临床药理学与治疗学 ›› 2018, Vol. 23 ›› Issue (2): 211-216.doi: 10.12092/j.issn.1009-2501.2018.02.018

小肠腺癌发病机制研究进展

宋彩霞^1,2，马强¹

¹兰州军区总医院消化科，兰州 730050，甘肃；²宁夏医科大学临床医学院，银川 750021，宁夏

收稿日期:2017-12-01 修回日期:2017-12-20 出版日期:2018-02-26 发布日期:2018-03-02
通讯作者: 马强，男，博士，硕导，研究方向：肠道肿瘤基础防治研究及小肠疾病临床研究。 Tel：0931-8994274 E-mail：maqiang.45@163.com
作者简介:宋彩霞，女，硕士研究生，研究方向：肠道肿瘤基础防治研究及小肠疾病临床研究。 Tel：0931-8994274 E-mail：songcx2321@163.com
基金资助:
国家自然科学基金（81374019）

Research progress in mechanisms of small bowel adenocarcinoma

SONG Caixia ^1,2, MA Qiang¹

¹ Department of Gastroenterology, General Hospital of Lanzhou Military Region, Lanzhou 730050, Gansu, China;² Ningxia Medical University Clinical Medical School, Yinchuan 750021, Ningxia, China

Received:2017-12-01 Revised:2017-12-20 Online:2018-02-26 Published:2018-03-02

摘要/Abstract

摘要：

小肠腺癌（small bowel adenocarcinoma, SBA）是临床相对罕见的恶性肿瘤，总体生存率低，预后差。近年研究表明，环境因素及遗传因素对其发病起一定作用。此外，多种基因突变、DNA甲基化、DNA错配修复和微卫星不稳定及相关信号通路异常激活参与了SBA的发生、发展。但其发病机制尚未完全阐明，需进一步深入研究，以期为SBA临床诊治及预后判断提供理论依据和新思路。

关键词: 小肠腺癌, 致癌因素, 分子机制

Abstract:

Small bowel adenocarcinoma (SBA) is a rare malignant tumor with poor prognosis and low overall survival. Researches of recent years have shown that the environmental factors and genetic factors play a role in the development of SBA. In addition, a variety of genetic mutations, DNA methylation, DNA mismatch repair, microsatellite instability and related signal pathways were activated abnormally involved in the occurrence and development of SBA. However, the pathogenesis of SBA is not completely clear and further research should be performed to provide theoretical basis and new ideas for the clinical diagnosis, treatment and prognosis of SBA.

Key words: small bowel adenocarcinoma, pathogenic factors, molecular mechanism

中图分类号:

R735.3+2

宋彩霞，马强. 小肠腺癌发病机制研究进展[J]. 中国临床药理学与治疗学, 2018, 23(2): 211-216.

SONG Caixia, MA Qiang. Research progress in mechanisms of small bowel adenocarcinoma[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 211-216.

参考文献

［1］Laforest A, Aparicio T, Zaanan A, et al. ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma［J］.Eur J Cancer,2014,50(10): 1740-1746.
［2］Overman MJ, Hu CY, Kopetz S, et al. A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease ［J］. Ann Surg Oncol, 2012, 19(5):1439-1445.
［3］Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012［J］. CA Cancer J Clin, 2012, 62:10-29.
［4］Bennett CM, Coleman HG, Veal PG, et al. Lifestyle factors and small intestine adenocarcinoma risk: A systematic review and meta-analysis［J］.Cancer Epidemiol, 2015, 39(3):265-273.
［5］Shenoy S. Genetic risks and familial associations of small bowel carcinoma ［J］. World J Gastrointest Oncol, 2016, 8(6):509-519.
［6］Schrock AB, Devoe CE, Mcwilliams R, et al. Genomic profiling of small-bowel adenocarcinoma ［J］. JAMA Oncol, 2017, 3(11):1546-1553.
［7］Jun SY, Lee EJ, Kim MJ, et al. Lynch syndrome-related small intestinal adenocarcinomas ［J］. Oncotarget, 2017, 8(13): 21483-21500.
［8］Zhang YF, Mao XY, Zheng JC, et al. Small intestine adenocarcinoma associated with Peutz-Jeghers syndrome: a report of 5 cases and literature review ［J］. J Clin Oncol, 2014, 13(7): 337-340.
［9］Svrcek M, Piton G, Cosnes J, et al. Small bowel adenocarcinomas complicating Crohn's disease are associated with dysplasia: a pathological and molecular study ［J］. Inflamm Bowel Dis, 2014, 20(9):1584-1592.
［10］Aparicio T, Zaanan A, Svrcek M, et al. Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment ［J］. Digest Liver Dis, 2014, 46(2): 97-104.
［11］Goh AM, Xue Y, Leushacke M, et al. Mutant p53 accumulates in cycling and proliferating cells in the normal tissues of p53 R172H mutant mice ［J］. Oncotarget, 2015, 6(20):17968-17980.
［12］Hsiao SJ, Remotti HE. Beta-catenin and p53 expression in ampullary and small intestinal adenocarcinoma ［J］. J Clin Oncol, 2013, 31(15): e14659.
［13］Chen L, Wu T, Pathology DO. Elevation of Notch1- and P53-immunoreactivity in small intestinal adenocarcinoma［J］. Chin J Histochem Cytochem, 2016, 2:130-135.
［14］ Pedersen LN, Krlev L, Teglbjrg PS, et al. Glutathione S -transferase genotype and p53 mutations in adenocarcinoma of the small intestine［J］. Scand J Gastroentero, 2003, 38(8):845-849.
［15］Gulhati P, Raghav K, Shroff RT, et al. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study［J］. Cancer, 2017, 123(6): 1011-1017.
［16］Freeman TJ, Smith JJ, Chen X, et al. Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of β-catenin［J］. Gastroenterol, 2012, 142(3): 562-571.
［17］郭文娟, 王爱英, 高春. 小肠腺癌组织的细胞凋亡及相关蛋白Bid和Bcl-xL的表达及意义［J］. 世界华人消化杂志, 2010, 18(11):1127-1133.
［18］Yang MC, Lin RW, Huang SB, et al. Bim directly antagonizes Bcl-xl in doxorubicin-induced prostate cancer cell apoptosis independently of p53 ［J］. Cell Cycle, 2016, 15(3):394-402.
［19］Jun SY, Kim M, Gu MJ, et al. Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma［J］. Mod Pathol, 2016, 29(4): 402-415.
［20］李小燕, 卢可, 张志,等. E-cadherin在小肠腺癌、小肠腺瘤中的表达及其意义［J］. 安徽医药, 2014,(11):2112-2114.
［21］Lee HJ, Lee OJ, Jang KT, et al. Combined loss of E-cadherin and aberrant β-Catenin protein expression correlates with a poor prognosis for small intestinal adenocarcinomas［J］. Am J Clin Patholo, 2013, 139(2):167-176.
［22］Alvi MA, Mcart DG, Paul K, et al. Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility［J］. Oncotarget, 2015, 6(25):20863-20874.
［23］Overman MJ, Pozadzides J, Kopetz S, et al. Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine ［J］. Brit J Cancer, 2010, 102(1):144-150.
［24］高峰, 王小云, 卢加杰,等. 小肠腺癌微卫星不稳定与hMLH1和hMSH2基因突变相关性分析［J］. 中华肿瘤防治杂志, 2014, 21(9):688-691.
［25］Zaaimi Y, Aparicio T, Laurentpuig P, et al. Advanced small bowel adenocarcinoma: Molecular characteristics and therapeutic perspectives ［J］. Clin Res Hepatol Gas, 2016, 40(2):154-160.
［26］Michel S, Kloor M, Singh S, et al. Coding microsatellite instability analysis in microsatellite unstable small intestinal adenocarcinomas identifies MARCKS as a common target of inactivation ［J］. Mol Carcinogen, 2010, 49(2):175-182.
［27］Kim KJ, Kim JY, Hong SM, et al. Loss of CADM4 expression is associated with poor prognosis in small intestinal adenocarcinomas［J］. Apmis, 2017, 125(5): 437-443.
［28］吴婧婧, 顾康生. 小肠腺癌患者中MMP-9、Ki-67、EGFR和VEGF的表达与临床特征及预后的相关性研究［J］. 安徽医科大学学报, 2013, 48(6):647-651.
［29］吴晓华, 张莘, 周文阔. 原发性小肠腺癌中 PTEN 蛋白及 PCNA 的表达及临床意义［J］. 河北医药, 2014(3):330-332.
［30］Suzuki H, Hirata Y, Suzuki N, et al. Characterization of a new small bowel adenocarcinoma cell line and screening of anti-cancer drug against small bowel adenocarcinoma ［J］. Am J Pathol, 2015, 185(2): 550-562.
［31］Zhang H, Zhang C. Expressions of filam in A and protein kinase B in small bowel adenocarcinoma and their significance［J］.J Transl Med, 2016,1:14-18.
［32］Hare LM, Phesse TJ, Waring PM, et al. Physiological expression of the PI3K-activating mutation Pik3ca(H1047R) combines with Apc loss to promote development of invasive intestinal adenocarcinomas in mice［J］. Biochem J, 2014, 458(2):251-258.
［33］Janku F, Tsimberidou AM, Garridolaguna I, et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors ［J］. Mol Cancer Ther, 2011, 10(3):558.
［34］ Pedersen K, Smyrk TC, Harrington S, et al. Programmed death-ligand 1 (PD-L1) expression in small bowel adenocarcinomas (SBA)［J］.J Clin Oncol,2015,33(15): 3619-3619.
［35］Thota R, Gonzalez RS, Berlin J, et al. Could the PD-1 pathway be a potential target for treating small intestinal adenocarcinoma ［J］? Am J Clin Pathol, 2017, 148(3):208-214.
［36］Xu C, Hua H, Chen T, et al. PD-L1 is correlated with p53 expression in patients with lung adenocarcinoma［J］. Int J Clin Exp Pathol, 2017,10(3):2701-2711.

[1]	张伟, 王迎斌, 曹璐, 刘艳, 张丽, 刘婕婷. 自噬在肠缺血再灌注损伤中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1061-1066.
[2]	郑莹, 张玲, 姚丽, 王乾合, 朱克祥. 聚腺苷二磷酸-核糖聚合酶抑制剂在胰腺癌中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(1): 108-115.
[3]	易虹, 顾兵, 陈玉年, 李华南. 中性粒细胞胞外诱捕网及其在痛风性疾病中的作用[J]. 中国临床药理学与治疗学, 2021, 26(10): 1167-1173.
[4]	乔大伟，李玉芳，肖云，姜礼双，卜平. 半枝莲抗结直肠癌及其转移机制研究进展[J]. 中国临床药理学与治疗学, 2019, 24(3): 332-336.
[5]	丁秋花，史道华. 二甲双胍抗肿瘤作用的分子机制研究进展[J]. 中国临床药理学与治疗学, 2019, 24(3): 350-354.
[6]	车晓航, 叶小磊, 陈春林. 抑郁症治疗非单胺作用靶标研究进展[J]. 中国临床药理学与治疗学, 2015, 20(8): 943-949.
[7]	张雪, 吴兰香, 张陶蓝, 温纯洁, 付利娟, 周宏灏. β-异硫氰酸苯乙酯多靶向抗肿瘤作用机制研究进展[J]. 中国临床药理学与治疗学, 2015, 20(2): 217-222.
[8]	贺春晖, 赵懿清, 李霞, 周路遥. 益母草碱药理作用的分子机制研究进展[J]. 中国临床药理学与治疗学, 2013, 18(12): 1419-1423.
[9]	张林, 李茂岚, 李松岗, 吴文广, 刘颖斌. 胆囊癌淋巴转移分子机制研究进展[J]. 中国临床药理学与治疗学, 2012, 17(8): 919-923.
[10]	赵吟, 李钦, 张信岳. 基于RBL-2H3细胞模型的I型过敏反应和类过敏反应研究[J]. 中国临床药理学与治疗学, 2010, 15(11): 1310-1314.

小肠腺癌发病机制研究进展

Research progress in mechanisms of small bowel adenocarcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 10

编辑推荐

Metrics

本文评价